MED CONSUMER WATCH · POLICY GUIDE
October's peptide policy: questions to put beside an offer
Read the policy documents, company plans and dated review corrections before comparing a peptide offer.
Published Sources checked
A headline can bring you to a provider's page before you have decided what you need from that page. Start by writing down the claim you are trying to check: the policy being cited, the product being discussed, or the service being offered. Keep those questions on separate lines. This guide follows the documents and explains the narrow corrections added to our older reviews.
The October 30 Federal Register notice describes a draft, nonbinding policy for certain peptide compounding under section 503A, while permanent listing proceeds through rulemaking.
Source 2Use this as a reading aid for a conversation, not as a decision about treatment. We have not inspected a manufacturer, pharmacy, batch or certificate, tested a product, or determined anyone's eligibility. A link to a document lets you inspect the basis for a statement; it is not a verification of the seller beside that link.
Compare identity and route
| Preparation | Route described |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral or topical. |
| Epitalon acetate | Subcutaneous or intramuscular; intermittent courses. |
| KPV acetate | Topical or oral. |
| MOTS-c acetate | Subcutaneous or intramuscular. |
| Semax free base | Intranasal. |
| TB-500 acetate | Subcutaneous or intramuscular. |
Read the conditions together
- Appendix A substance.
- Appendix B identity and route, including sequence, structure, formula, molecular weight.
- Section 510-registered facility; valid certificate of analysis (COA), identifying/characterizing substance with Appendix B test results.
- Original manufacturer: FDA registration, CGMP/FD&C compliance, physical location on COA; FDA-registered intermediaries themselves perform/document appropriate manufacturer/COA validation.
- Compounders report products, serious adverse events regardless of causality, and quality issues to FDA and compounding/destination states; MedWatch; patient labels explain event/quality reporting. Product reports: active ingredient/unit strength, original manufacturer/unique facility identifier, dosage form/route.
- Label: “This is a compounded drug product. Not for resale.”
- Only one active ingredient, listed in Appendix A.
- Oral forms: document adequate human bioavailability of the specific supplied formulation.
- Only co-packaged/drug-containing device: FDA 510(k)-cleared syringe.
- Other FD&C requirements, including sanitation and patient-specific prescriptions.
Read the notice's status before the sales page
The notice describes when HHS intends to refrain from enforcement against state-licensed pharmacies, federal facilities and licensed physicians using listed substances. It says HHS may revisit the policy for safety signals or quality problems. Publication establishes the notice's date, not a separate effective date or permanent listing decision. We read its section 503A scope as limited, not as new authorization under section 503B.
Source 2Keep a copy of the exact document and the date you read it. If an explanation points to a different version, ask for that version and the passage being relied on. In your notes, record the unresolved question rather than replacing it with an assumption. This also makes it easier to revisit an answer when another document appears.
Turn the company announcement into questions
Hims & Hers' October 29 Peptides+ announcement is a preview. BPC-157 and TB-500 are planned only when allowable; the announcement is not confirmation of current dispensing.
Source 3The announced plans include Sermorelin, Glutathione, B12, NAD+ and L-carnitine, with independent providers and licensed pharmacies. The company acknowledges limited published research and cautions that timing, availability and future results may differ from expectations.
Source 3A waitlist, an intake, a prescription and a delivered order are different events. Ask which event an answer describes. Keep any response with the dated page it refers to, and request a fresh written description of the proposed service before relying on an older review. We have not checked a current order, patient account or fulfillment record.
Why two older reviews have corrections
FDA separates current Category 2 entries from previously listed substances whose nominations were withdrawn. BPC-157 and CJC-1295 appear in the latter group. It retains concerns about immune reactions for certain routes, peptide impurities and characterization, with limited safety information for BPC-157 and limited clinical data for CJC-1295. It also identifies serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.
Source 5Our Live Vital and Research Labs pages contained regulatory wording that needed this distinction. The correction addresses that wording. It is not a new assessment of their offerings, prices, facilities, testing or clinical claims. Read the correction alongside the older publication date; do not use it as a fresh endorsement of the rest of the review.
Keep product approval and oversight separate
FDA does not approve compounded drugs or check their safety, effectiveness and quality before marketing. They are different from FDA-approved generic drugs. Poor compounding can cause contamination or incorrect ingredient strength, with serious consequences.
Source 4FDA distinguishes compliant 503A compounding, which is exempt from CGMP requirements, from 503B outsourcing, which is subject to them. Sanitary conditions still matter in either setting.
Source 4On your comparison sheet, give the manufacturer, compounder, prescriber and seller separate rows. Put each assertion in the row for the organization it names. Ask for clarification when the named entity changes between a sales page and a document; do not merge those identities in your notes.
Questions and answers
What should I bring to a discussion?
Bring the dated offer, the exact product wording, the source link being cited and a short list of unanswered questions. Ask the clinician to explain the proposed purpose and the alternatives in your circumstances. Keep the clinical explanation separate from your notes about payment, delivery and cancellation.
What does FDA suggest when evaluating an online service?
FDA advises researching online pharmacies and discussing prescription questions with a healthcare professional. It warns that consumers may not know which compounder made an online product or whether appropriate licensing and quality standards apply.
Source 4Does this update refresh the whole older review?
No. The dated notes identify the specific policy context or wording changed. The older vendor research and clinical discussions have not been rechecked as part of this update. Read their dates and ask for current information relevant to the particular offer you are considering.
Sources
- PolicyHHS
- October 30 noticeFederal Register
- Peptides+ announcementHims & Hers
- Compounding questions and answersFDA
- Compounding safety concernsFDA